A Phase 3 interventional study of Blood sampling, endoscopy and budesonide-MMX® 6 mg in Ulcerative Colitis, sponsored by Bausch Health Americas, Inc.. Completed at 105 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-12-10.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Bausch Health Companies Inc..
Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., this one is the 2nd largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 3, and was the 5th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 5–17
Bausch Health Americas, Inc.
Ages 5–17
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 510 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 273 across the 18 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.
1 of the studies in Colitis, Ulcerative by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04314375Bausch Health Americas, Inc.Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare Budesonide MMX™ 6 mg and Budesonide MMX™ 9 mg tablets to placebo and to Asacol 6x 400 mg tablets over an 8-week treatment period to determine if Budesonide MMX™ is effective in the treatment of ulcerative colitis.
Each patient will receive one of the following regimens in the morning after breakfast:
Each patient will also receive on each day after the midday meal and after the evening meal either:
Hence, each patient is to take seven tablets per day of active or placebo study medication as per the randomization schedule. Placebo tablets of budesonide-MMX™ and placebo over-encapsulated tablets of Asacol® will be used to maintain the study blind using a double-dummy technique.
During the study, five visits to the clinical center are scheduled: one at Screening and three in the double-blind treatment period (Day 1, Day 14, Day 28 and Day 56). A safety follow up visit will take place about 2 weeks after the final study visit. If a patient is withdrawn from the study before Day 56, they will be asked to attend the study center as soon as possible thereafter so that the Final visit assessments can be conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients fulfilling the following criteria at the screening visit are eligible for participation in the study:
Exclusion Criteria:
Patients who meet any of the following criteria at screening visit are to be excluded from study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Procedure: Blood sampling, endoscopy · Drug: budesonide-MMX® 6 mg
One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Procedure: Blood sampling, endoscopy · Drug: budesonide-MMX® 9 mg
Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Procedure: Blood sampling, endoscopy · Drug: Placebo
Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Procedure: Blood sampling, endoscopy · Drug: Asacol® 400 mg
Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
6 mg/day, 6 mg tablets
9 mg/day, 9 mg tablets
Placebo
2400 mg/day, 400 mg tablets
Clinical and Endoscopic Remission.
Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.
Time frame: 8 weeks
Clinical Improvement.
Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.
Time frame: 8 weeks
Endoscopic Improvement
Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8. As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.
Time frame: 8 weeks
Recruited from August 2008 until May 2010.
| Milestone | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Started | 126 | 127 | 129 | 127 |
| Completed | 89 | 89 | 76 | 95 |
| Not completed | 37 | 38 | 53 | 32 |
| Withdrew: Adverse event | 5 | 6 | 10 | 7 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 8 | 11 | 10 | 9 |
| Withdrew: Lost to follow-up | 1 | 5 | 4 | 2 |
| Withdrew: Physician decision | 3 | 2 | 2 | 2 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 13 | 9 | 14 | 8 |
| Withdrew: Infectious colitis, normal histology | 5 | 4 | 8 | 3 |
| Withdrew: Randomization error, return to prior rx | 0 | 0 | 3 | 0 |
Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.
| percentage of patients | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Clinical and Endoscopic Remission. | 13.2 (7.2 to 19.3) | 17.9 (11.1 to 24.7) | 7.4 (2.8 to 12.1) | 12.1 (6.4 to 17.8) |
Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.
| percentage of patients | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Clinical Improvement. | 30.6 (22.4 to 38.8) | 33.3 (25.0 to 41.7) | 24.8 (17.1 to 32.5) | 33.9 (25.5 to 42.2) |
Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8. As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.
| percentage of patients | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Endoscopic Improvement | 35.5 (27 to 44.1) | 41.5 (32.8 to 50.2) | 33.1 (24.7 to 41.4) | 33.1 (24.8 to 41.3) |
Collected over 56 day ± 2 day (study duration) + 30 day safety followup period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1: Budesonide-MMX® 6 mg | — | 2/126 (1.6%) | 35/126 (27.8%) |
| 2: Budesonide-MMX® 9 mg | — | 3/127 (2.4%) | 36/127 (28.3%) |
| 3: Placebo | — | 3/129 (2.3%) | 34/129 (26.4%) |
| 4: Asacol® 400 mg | — | 4/127 (3.1%) | 31/127 (24.4%) |
| Event | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/126 | 3/127 | 1/129 | 1/127 |
| Cerebrovascular accidentNervous system disorders | 1/126 | 0/127 | 0/129 | 0/127 |
| DiarrhoeaGastrointestinal disorders | 0/126 | 1/127 | 0/129 | 0/127 |
| Large intestine perforationGastrointestinal disorders | 0/126 | 1/127 | 0/129 | 0/127 |
| PancreatitisGastrointestinal disorders | 0/126 | 0/127 | 0/129 | 1/127 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 0/127 | 0/129 | 1/127 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/126 | 1/127 | 0/129 | 0/127 |
| Pyoderma gangrenosumSkin and subcutaneous tissue disorders | 0/126 | 0/127 | 0/129 | 1/127 |
| Pelvic abscessInfections and infestations | 0/126 | 0/127 | 1/129 | 0/127 |
| Deep vein thrombosisVascular disorders | 0/126 | 0/127 | 1/129 | 0/127 |
| Event | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 15/126 | 12/127 | 20/129 | 12/127 |
| HeadacheNervous system disorders | 17/126 | 8/127 | 19/129 | 12/127 |
| Abdominal painGastrointestinal disorders | 2/126 | 6/127 | 8/129 | 10/127 |
| NauseaGastrointestinal disorders | 5/126 | 5/127 | 8/129 | 10/127 |
| PyrexiaGeneral disorders | 5/126 | 3/127 | 9/129 | 3/127 |
| InsomniaPsychiatric disorders | 6/126 | 5/127 | 9/129 | 3/127 |
| DiarrhoeaGastrointestinal disorders | 5/126 | 1/127 | 7/129 | 8/127 |
| FlatulenceGastrointestinal disorders | 1/126 | 1/127 | 2/129 | 7/127 |
| Back painMusculoskeletal and connective tissue disorders | 4/126 | 5/127 | 7/129 | 2/127 |
| DizzinessNervous system disorders | 6/126 | 0/127 | 1/129 | 4/127 |
Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3\[infectious colitis\] - 17\[normal histology at baseline\] = 489).
| Age, Categorical(Participants) | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 117 | 122 | 115 | 118 | 472 |
| >=65 years | 4 | 1 | 6 | 6 | 17 |
| Age, Continuous(years) | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg | Total |
|---|---|---|---|---|---|
| Mean | 43.2 ± 13 | 41.7 ± 12.2 | 41.7 ± 13.6 | 44 ± 12.4 | 42.7 ± 12.8 |
| Sex: Female, Male(Participants) | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg | Total |
|---|---|---|---|---|---|
| Female | 62 | 46 | 53 | 55 | 216 |
| Male | 59 | 77 | 68 | 69 | 273 |
| Region of Enrollment(participants) | 1: Budesonide-MMX® 6 mg | 2: Budesonide-MMX® 9 mg | 3: Placebo | 4: Asacol® 400 mg | Total |
|---|---|---|---|---|---|
| United States | 75 | 76 | 77 | 76 | 304 |
| Canada | 5 | 7 | 5 | 6 | 23 |
| India | 41 | 40 | 39 | 42 | 162 |
Showing the first 100 of 105 sites across 4 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2008, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 4 years 3 months after primary completion. A results delay was requested in Dec 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bausch Health Americas, Inc. →